Vitality Watch

Dossier clinicaltrials trial early 21-sep-2026
Small or early-phase human trial or pilot study

The Revitalize Study in Older Adults at Risk for Alzheimer’s Disease

Key claim: The Revitalize Phase II trial will test whether 12 weeks of transcranial and intranasal near-infrared photobiomodulation, versus sham, improves cognition, 31P-MRS ATP markers of mitochondrial function, and resting-state connectivity in older adults at elevated Alzheimer’s risk.

Abstract

The goal of this multi-site double blinded randomized sham-controlled Phase II clinical trial is to test a novel, relatively low cost, low risk, and potentially high impact therapeutic intervention in older adults who are at increased risk for Alzheimer’s disease. The intervention involves transcranial and intranasal delivery of near infrared (NIR) light via light emitting diodes, aka photobiomodulation (PBM). The overall hypothesis, based on animal and pilot studies, is that exposure to NIR stimulation will have beneficial effects on brain health via influence on mitochondrial function as measured by changes in 31Phosphorous (31P) MRS-based markers of ATP, neural network changes in functional connectivity (rs-fMRI), and improved cognitive performance. To test this hypothesis, 168 older adults with subjective cognitive complaints, and a first-degree family history of Alzheimer’s disease will be randomized to sham or real treatment groups. Neuroimaging and cognitive outcome measures will be obtained, before and after a 12-week intervention involving transcranial and intranasal NIR-PBM. The intervention protocol will involve “lab” and “home” sessions, and a 3 month post-intervention follow-up. This trial will determine: 1) whether NIR stimulation, relative to sham, improves performance on memory and executive tasks sensitive to hippocampal and frontal brain function in older adults with increased risk for Alzheimer’s disease; 2) whether NIR stimulation, relative to sham, enhances brain function and connectivity measured by changes in MRS phosphorous ATP and resting state functional connectivity; and 3) how differences in demographic, neuroimaging, and Alzheimer-related risk factors influence the brain response to NIR stimulation versus sham in older adults with increased risk for Alzheimer’s disease. Results will provide key insights into whether this novel NIR intervention can enhance cognition in older adults with increased risk for Alzheimer’s disease and will provide the necessary data for a future Phase III randomized clinical trial.

Why this matters

Transcranial and intranasal near-infrared photobiomodulation is spreading through consumer devices and clinic offerings well ahead of controlled human data, so a registered multi-site Phase II sham-controlled trial in an AD-risk population is a meaningful trajectory event for the modality. The endpoints — 31P-MRS ATP and resting-state connectivity alongside cognition — would, if positive, be the first mechanistic-plus-clinical readout of the mitochondrial story the trend has been promoting. Until then, the trial’s existence is a signal about where the field is headed, not evidence for the claims already being made.

Source

Link

Briefing card

The Revitalize Study in Older Adults at Risk for Alzheimer's Disease
Stage: trial early · clinicaltrials · 21-sep-2026

If you are using a transcranial or intranasal red-light device for brain health, the definitive test in AD-risk older adults is only now enrolling — no efficacy result exists yet.

The Revitalize Phase II trial will test whether 12 weeks of transcranial and intranasal near-infrared photobiomodulation, versus sham, improves cognition, 31P-MRS ATP markers of mitochondrial function, and resting-state connectivity in older adults at elevated Alzheimer's risk.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT04018092

build build 880 · 2bcef25 · 2026-11-18